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Abstract: Drugs for asthma and other chronic obstructive diseases of the lungs should be 
preferably delivered by the inhalation route to match therapeutic effects with low systemic 
exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose 
inhalers and dry powder inhalers, each characterized by speciﬁ  c inhaler technique and instructions 
for use. The patient–device interaction is part of the prescribed therapy and can have a relevant 
impact on adherence and clinical outcomes. The most suitable device should be considered 
for each patient to assure the correct drug intake and adherence to the prescribed therapy. The 
development of new drugs/devices in the past decades improved the compliance with inhaler 
and possibly drug delivery to the bronchi. The present review focuses on the recently developed 
beclomethasone/formoterol extraﬁ  ne ﬁ  xed combination and technical aspects of drug delivery 
to the lungs in patient’s perspective.
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Introduction
Inhaled therapy, which was developed within the last 50 years, is the cornerstone of 
asthma management and will remain so for the near future (GINA 2007). Although 
the effectiveness of inhaled therapy was reported as early as the beginning of the 
20th  century, it did not ﬁ  nd widespread use until mid century, after the introduction 
of the ﬁ  rst propellant gas dosing aerosols in the form of pressurized metered dose 
inhalers (pMDIs). Direct delivery of aerosolized asthma drugs to the lower airways is 
advocated to relieve airﬂ  ow limitation and to suppress inﬂ  ammation. In comparison 
with oral therapy, the inhaled route provides maximum beneﬁ  t with minimum effective 
doses and few adverse effects. However, several factors, including drug formulation, 
delivery device, and the patient’s skills, inﬂ  uence use of the inhaled route.
Currently available drugs for asthma treatment, including short- and long-acting 
bronchodilators alone or in combination and corticosteroids alone or in combination 
with bronchodilators, are all effective and reasonably safe (GINA 2007). The goal of 
asthma treatment, as deﬁ  ned in the recent guidelines update (GINA 2007; NAEPP 
2007), is to reach and maintain asthma control, deﬁ  ned as minimal symptoms, no 
exacerbations, and no limitation of activities, together with normal lung function.
Most studies in recent years have shown that asthma can be well controlled in most 
patients with inhaled steroids alone or in combination with long-acting beta2 agonists 
(LABA) (O’Byrne et al 2001; Bateman et al 2004; Rabe et al 2006). In contrast, epi-
demiological studies show that, overall, asthma is not adequately treated (and thus not 
controlled) in patients in the “real world,” probably because they behave differently 
from patients studied in randomized controlled trials: those patients are selected for 
their adherence to treatment and their ability to use the inhaler devices correctly. Therapeutics and Clinical Risk Management 2008:4(5) 856
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A recent publication (Cazzoletti et al 2007) evaluated 
asthma control across European countries; the prevalence 
of uncontrolled asthma ranged from 20% in Iceland to 67% 
in Italy, conﬁ  rming previous observations (Rabe et al 2000; 
Partridge et al 2006).
The clinical beneﬁ  t provided by inhaled therapy depends 
on several factors. From the patient’s perspective, adherence 
to treatment and ability to inhale the drug seem to be the 
most important. Correct inhaler technique is a key factor in 
ensuring that the drug is deposited in the bronchi, where the 
pharmacological effect has to take place. Inadequate inhala-
tion technique has been associated with loss of asthma control 
(Giraud and Roche 2002).
Despite the clinical importance of inhaled therapy, cur-
rent guidelines lack consensus on recommended devices. In 
evidence-based guidelines for device selection (Brocklebank 
et al 2001; Dolovich et al 2005), all randomized controlled 
studies in which the same drug was delivered with different 
devices have been reviewed. None of the pooled meta-
analyses showed a signiﬁ  cant difference between devices in 
any efﬁ  cacy outcome. The conclusions of these guidelines 
are that devices used for the delivery of bronchodilators and 
steroids can be equally efﬁ  cacious, provided that patients use 
the correct technique for inhalation. Therefore, the selection 
criteria should be mainly related to the patient’s age, prefer-
ence, and ability to use the selected device correctly, rather 
than to a difference in clinical efﬁ  cacy.
This review focuses on management issues in the treat-
ment of asthma, provides an overview of pharmacology 
and rationale for the use of combinations, and discusses 
speciﬁ  c formulation characteristics and clinical efﬁ  cacy of 
the beclomethasone/formoterol combination from patient-
focused perspectives.
Technical aspects of inhaled therapy
The aim of inhaled therapy is to allow the medication to 
reach the site of structural and functional alterations of the 
airways. This can be obtained by satisfying the following 
conditions: (i) the drug delivery should allow the penetration 
of inhaled particles into the respiratory tract; (ii) the formula-
tion should enable the drug to deposit along the respiratory 
tract; and (iii) the deposition of the drug should translate 
into functional and clinical beneﬁ  ts. Taken together, these 
conditions require careful attention to the choice of device 
(Brocklebank et al 2001).
The relative deposition pattern of the inhaled drug is 
the result of a complex interaction between the device, the 
aerosol formulation, and the patient’s inhalation technique. 
To allow the medication to reach the target site of action, a 
variety of hand-held inhalation devices has been introduced 
in clinical practice. The devices differ in terms of technical 
design, actuation (eg, inspiratory ﬂ  ow rate), composition 
(eg, characteristics of the propellant), vehicle, dose per 
inhalation, user-friendliness and cost.
The pMDI is the most widely used device (Virchow et al 
2008). Since its introduction in 1956, it has been widely 
prescribed by health care professionals. The major limitation 
of the pMDI is the fast-moving aerosol, which increases the 
deposition of the drug in the pharynx, is responsible for local 
side effects (candidiasis, dysphonia) and does not contribute 
to clinical efﬁ  cacy. The drug contained in the MDI canister 
can be formulated as a suspension or a solution, which 
have different properties in terms of delivery characteristics 
(particle size, plume velocity and duration) and user-
friendliness. For years, MDI-formulated drugs have been 
mainly suspension formulations delivering large particles, 
thus reaching the lower airways at only 10% to 20% of the 
nominal dose, and propelled by chloroﬂ  uorocarbons (CFC) 
(Barnes 1995). A suspension formulation is obtained when 
the active drug is nonsoluble in the propellant and therefore 
remains in the form of solid powder inside the canister. To 
favor homogeneity of the drug concentration and consequent 
dose consistency and reproducibility, suspension formula-
tions, unlike solutions, need to be shaken before inhalation 
to allow uniform distribution of solid powder particles of the 
drug. Unfortunately, 14% to 25% of patients do not shake 
the device properly (Van der Palen et al 1999), resulting in 
a variable amount of the drug being emitted for each puff. 
Moreover, suspension formulations need to be delivered with 
a relatively larger diameter of the oriﬁ  ce to avoid its blockage 
by the emitted drug. This leads to higher velocity and lower 
duration of the aerosol plume – resulting in increased drug 
deposition in the oropharynx – and requires coordination 
between actuation of the device and inhalation by the patient. 
In patients with poor coordination, the use of a spacer is often 
recommended to overcome this limitation.
Dry powder inhalers (DPIs) were introduced into clinical 
practice in the 1950s. Three types of DPIs are available with 
different handling instructions: single-dose (eg, Handihaler®, 
Aerolizer®), multiple-dose (ie, Diskus®), and reservoir 
(ie, Turbuhaler®). DPIs do not need coordination, as the 
drug is not driven by the propellant but is delivered by the 
inhalation effort. For this reason, MDIs and DPIs require dif-
ferent techniques: slow and deep inhalation (MDIs) or quick, 
forceful, and deep inhalation (DPIs). The actuation of some 
DPI devices needs high inspiratory ﬂ  ow to ensure optimal Therapeutics and Clinical Risk Management 2008:4(5) 857
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drug delivery: both the particle size of emitted powder and 
the amount of drug suitable to reach the lower airways are 
dependent on the patient’s peak inspiratory ﬂ  ow (Tarsin et al 
2006). A recent study demonstrates that elderly patients are 
the least likely to generate high inspiratory ﬂ  ows, irrespective 
of the presence of airway obstruction (Janssens et al 2008).
Although DPI devices do not require coordination, they 
may be managed incorrectly by patients, resulting in a poor 
level of disease control; Wieshammer and Dreyhaupt (2008) 
reported that inhaler-speciﬁ  c error rates ranged from 9.1% to 
53.1% and increased with age and with the severity of airway 
obstruction (p  0.01). While MDIs share the same inhalation 
technique, each DPI device requires speciﬁ  c training, which 
may contribute to the increased risk of errors. Furthermore, 
the frequency of inhalation errors increased from 29% to 39% 
in adult asthmatics when multiple inhalers were prescribed 
(Van der Palen et al 1999).
In recent decades, possible adverse effects on health and 
the environment as a result of the destruction of the earth’s 
ozone layer by CFC paved the way for the ban of these 
compounds under the Montreal Protocol (Hartung et al 2002; 
Newman, 1990). New propellants without ozone-damaging 
properties – hydroﬂ  uoroalkanes (HFA) – have been devel-
oped, and reformulated, environmentally friendly inhalers 
have been shown to be nontoxic, safe, and effective. Exist-
ing drugs can be formulated as HFA suspensions or HFA 
solutions (Figure 1).
The switch to HFA suspensions is possible when drugs 
that were suspended in CFC propellant are also suited to 
being suspended in HFA propellant while maintaining the 
same particle size, pattern of deposition, pharmacokinetics, 
efﬁ  cacy, and safety proﬁ  le. For example, ﬂ  uticasone propio-
nate in the new suspension with HFA propellant maintains 
the same dosage recommendations as the previous CFC 
formulation (NAEPP 2007).
The switch to HFA solutions – the reformulation of former 
CFC suspensions – is possible when the drug is soluble in 
HFA propellant (or co-solvents). In this case the solution 
is compatible with devices with smaller oriﬁ  ce diameters, 
leading to lower velocity and higher duration of the aerosol 
plume, thus facilitating the patient’s coordination between 
actuation of the device and inhalation. Moreover, because 
the drug is dissolved in the propellant, solutions can be 
tailored to extraﬁ  ne drug delivery, reducing the particle size 
of emitted aerosol and thereby allowing deeper penetration 
in the bronchial tree. Switching from a CFC pMDI to an 
HFA pMDI was well accepted by most patients in one study 
(Hartung et al 2002): the taste was described as good and 
sweet, and the softer and slower jet was appreciated.
Recent developments in inhaled 
therapy devices: Modulite® 
technology
The Chiesi Modulite platform technology allows the size 
and distribution of particles to be tailored for the speciﬁ  c 
airway targets. This is done through the manipulation of 
inhaled HFA-based solution pMDI formulations by acting 
CFC
suspension
HFA
suspension
HFA
solution
Non-extrafine extrafine
Figure 1 Reformulation from CFC-propelled to HFA-propelled pMDIs.
Abbreviations: HFA, hydroﬂ  uoroalkanes; CFC, chloroﬂ  uorocarbons; pMDI, pressurized metered dose inhaler.Therapeutics and Clinical Risk Management 2008:4(5) 858
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on a number of variables, including formulation components 
and actuator orifice diameter (Acerbi et al 2007). This 
technology offers the opportunity to match the CFC-based 
pMDIs with the HFA MDIs, thus favoring the transition to 
environmentally friendly formulations. This kind of switch 
has been successfully achieved for corticosteroids such as 
beclomethasone and budesonide (Bousquet and Cantini 
2002; Vastagh et al 2003). Moreover, by virtue of the solu-
tion formulation, this technology can be used to produce 
extraﬁ  ne aerosols, such as the beclomethasone dipropionate/
formoterol ﬁ  xed combination (BDP/F), which provides a 
homogeneous distribution of the two active drugs throughout 
the entire bronchial tree.
Formulative characteristics 
of inhaled BDP/F extraﬁ  ne
ﬁ  xed combination
The BDP/F 100/6 HFA pMDI combination is an extraﬁ  ne 
solution formulation in which the BDP dose is 2.5-fold lower 
than the conventional BDP CFC product (100 μg of BDP 
per actuation instead of 250 μg of non-extraﬁ  ne BDP). The 
reduction in BDP nominal dose, together with the extraﬁ  ne 
particle size, allows a similar dose of the drug to reach the 
lower airways and less drug to be deposited in the upper 
airways, potentially improving the efﬁ  cacy/safety ratio. 
The formoterol component in BDP/F is not associated with 
nominal dose reduction (Dhillon and Keating 2006).
There is considerable literature available on BDP, 
covering all relevant outcomes in asthma treatment in both 
adults and children. In the only available study showing that 
inhaled corticosteroids (ICS) reduce asthma mortality (Suissa 
et al 2000), 93% of the prescribed canisters contained low-
dose BDP. Formoterol is the only fast, long-acting broncho-
dilator with dose-dependent effects (McGavin et al 2001) and 
well-documented efﬁ  cacy and safety in obstructive diseases 
(Prenner 2007); it can also be used as a reliever medication 
in asthma, provided the patient is receiving regular ICS 
treatment (GINA 2007).
The rationale for developing an extraﬁ  ne formulation lies in 
the fact that asthma is characterized by airway inﬂ  ammation and 
remodeling in all parts of the airways, including small airways 
(Hamid et al 1997; Tulic et al 2001). Therefore, the optimized 
drug deposition that results from reduced particle size may lead 
to improved clinical beneﬁ  ts. Extraﬁ  ne BDP has proved to be 
effective on candidate markers of peripheral airway inﬂ  amma-
tion (Gershman et al 1999; Hauber et al 2006).
Since extraﬁ  ne particles are expected to improve drug 
delivery to the respiratory tree, the lung deposition and 
distribution pattern of BDP/F were recently assessed using 
a gamma-scintigraphic technique (Mariotti et al 2007). The 
average lung deposition was 34% relative to the nominal dose 
in healthy subjects and 31% in patients with asthma, suggesting 
that good delivery to the lung can be achieved regardless 
of the underlying pathophysiological condition (Figure 2). 
Table 1 compares lung deposition of different inhaler device 
categories.
Moreover, because the drug is delivered to both central and 
peripheral airways (Figure 3), a uniform treatment of inﬂ  amma-
tion and bronchoconstriction throughout the lung is expected.
healthy asthmatic
Figure 2 Scintigraphic images of deposition of BDP/F combination in a healthy subject and an asthmatic patient determined by γ-scintigraphy after inhalation of four shots of 
BDP/formoterol combination labelled with 99 mTc, a γ-emitting isotope (Mariotti et al 2007).
Abbreviation: BDP/F beclomethasone dipropionate/formoterol.Therapeutics and Clinical Risk Management 2008:4(5) 859
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Rationale for ICS-LABA 
combinations
ICS represent the mainstay of persistent asthma therapy and 
the addition of LABAs is the preferred option for patients 
whose asthma is not controlled with low doses of ICS alone 
(GINA 2007). The therapeutic value of ICS/LABA combi-
nations is increased by the evidence suggesting that LABA 
and ICS mutually potentiate their effects when given in 
combination (Barnes 2002; Caramori et al 2006). Possible 
mechanisms of synergistic interactions include (i) the 
increase in expression of beta2 receptors (ie, adrenergic 
receptors mediating smooth muscle relaxation in the 
airways) by increasing gene transcription induced by ICS 
leading to a greater number of receptors available for beta2 
agonists (Scott et al 1999), (ii) the increase in the nuclear 
localization of glucocorticoid receptors induced by beta2 
agonists potentiating the antinﬂ  ammatory mechanisms of 
ICS (Eickelberg et al 1999), and (iii) the direct synergic 
action of both drugs on the release of inﬂ  ammatory mediators 
promoting a more pronounced antiinflammatory effect 
(Caramori et al 2006).
The complementary effects of the combination of BDP 
and formoterol on the inﬂ  ammatory process in patients with 
asthma were investigated in sputum-derived inﬂ  ammatory 
cells in vitro (Proﬁ  ta et al 2005). Antiremodeling and antipro-
liferative effects were documented in human lung ﬁ  broblasts 
(Descalzi et al 2008). The ﬁ  ndings of these studies indicate 
that the BDP/F combination induces a favorable pharmaco-
dynamic interaction that can produce added beneﬁ  ts in terms 
of bronchodilation, antiinﬂ  ammatory, antiremodeling, and 
antiproliferative effects.
Clinical characteristics 
of the beclomethasone/formoterol 
(BDP/F) ﬁ  xed combination
Although beclomethasone and formoterol are well-known 
molecules of proven efﬁ  cacy and safety, the clinical develop-
ment of the BDP/F combination involved a series of clinical 
trials carried out in more than 1500 patients suffering from 
different levels of asthma severity. The pharmacokinet-
ics proﬁ  le of inhaled BDP/F extraﬁ  ne ﬁ  xed formulation 
was assessed in a 3-way crossover study (Poli et al 2006), 
which compared single doses of BDP/F 400/24 μg, or an 
equipotent non-extraﬁ  ne regimen of BDP and formoterol 
given via separate inhalers (1000 μg BDP non-extraﬁ  ne 
and 24 μg formoterol) or placebo. Plasma levels of the 
active metabolite of BDP, B-17-MP, in the ﬁ  rst 30 min 
(area under the curve from time 0 to 30 min [AUC0–30 min]), 
which can be considered an index of pulmonary deposition, 
were 86% greater with the ﬁ  xed combination than with the 
separate inhalers. However, the 24 h systemic exposure of 
B-17-MP was 35% lower with the ﬁ  xed combination than 
with the separate inhalers. No difference between ﬁ  xed 
combination and separate inhalers was shown for systemic 
exposure of formoterol.
In another study, asthmatic patients regularly treated 
for 4 weeks with BDP/F 100/6 μg as 2 inhalations twice 
daily (Singh et al 2008) were given 10 additional doses of 
BDP/F 100/6 μg, formoterol 6 μg, or placebo on 3 different 
days (days 14, 21 and 28 of the study) to investigate the 
safety and effects of the two drugs. Compared with high-
dose BDP/F and placebo, serum potassium signiﬁ  cantly 
decreased only with high-dose formoterol. Changes in vital 
signs, including heart rate and blood pressure, corrected 
Table 1 Lung deposition of different inhaler device categories (data 
from multiple studies)
Lung deposition %
BDP/F pMDI (Mariotti et al 2007) 31%
Conventional pMDIs (Selroos et al 1996) 10%–20%
Conventional pMDIs plus spacer 
(Selroos et al 1996)
20%–30%
DPIs (Anderson 2001) 15%–25%
Abbreviations: BDP/F,  beclomethasone dipropionate/formoterol;  pMDI,  pressurized 
metered dose inhaler; DPI, dry powder inhaler.
peripheral
34%
central 
66%
Figure 3 Percentage of central and peripheral lung deposition of radiolabeled BDP/F 
solution in 8 asthmatic patients. Lung contours for the assessment of regional deposi-
tion were assessed from an 81mKrypton-ventilation scan after inhalation of 4 shots 
of BDP/formoterol combination labelled with 99 mTc, a γ-emitting isotope (adapted 
from Mariotti et al 2007).
Abbreviation: BDP/F, beclomethasone dipropionate/formoterol.Therapeutics and Clinical Risk Management 2008:4(5) 860
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QT intervals, and plasma lactate levels were similar with 
high-dose BDP/F and high-dose formoterol but not consid-
ered clinically signiﬁ  cant. This result demonstrates that, in 
patients with asthma, the administration of high cumulative 
doses of BDP/F in addition to maintenance therapy has a 
satisfactory tolerability proﬁ  le and is at least as safe as the 
administration of high doses of formoterol alone.
A preliminary trial (Dhillon and Keating 2006; Rigamonti 
et al 2006) suggested that BDP extraﬁ  ne 100 μg/actuation, 
developed as a single agent, is clinically equivalent to 
BDP non-extraﬁ  ne pMDI 250 μg/actuation in patients with 
moderate asthma, demonstrating a 1:2.5 equivalence ratio 
between extraﬁ  ne and non-extraﬁ  ne BDP – a result already 
documented for a previously developed formulation (Vanden 
Burgt et al 2000).
The efficacy of the BDP/F fixed combination was 
then evaluated in a 3-month randomized controlled trial 
conducted in patients with moderate asthma who were 
still symptomatic despite receiving low-dose ICS – up to 
500 μg/day BDP or equivalent (Dhillon and Keating 2006; 
Bonnet-Gonod et al 2006a). BDP/F given as one inhalation 
twice daily proved to be more effective at improving lung 
function than a double equipotent dosage of BDP non-
extraﬁ  ne. A second investigation was carried out in patients 
with more severe asthma, documented by recurrent symp-
toms and impaired lung function despite treatment with up 
to 1000 μg/day BDP or equivalent (Dhillon and Keating 
2006; Bonnet-Gonod et al 2006b). In this setting, BDP/F 
given as 2 inhalations twice daily for 6 months showed 
improvement in peak expiratory ﬂ  ow (PEF) and forced 
expiratory volume in 1 s (FEV1) comparable with that of 
an equipotent non-extraﬁ  ne regimen of BDP and formoterol 
administered via separate inhalers, and proved to be more 
effective than 1000 μg/day BDP non-extraﬁ  ne. Moreover, 
the BDP/F ﬁ  xed combination was superior to both BDP 
plus formoterol in separate inhalers and BDP monotherapy 
in terms of percentage of clinical measures of asthma 
control, suggesting that patients receiving extraﬁ  ne BDP/F 
may experience additional beneﬁ  ts that extend beyond 
improvements in pulmonary function. The percentage of 
patients with asthma exacerbations requiring oral steroids 
(percentage referred to patients with severe exacerbations) 
was lower in the group treated with the BDP/F ﬁ  xed combi-
nation (6.0%) than in those receiving BDP plus formoterol 
separately (12.1%) or BDP alone (14.1%). Mean morning 
serum cortisol levels at week 24 were signiﬁ  cantly higher in 
the BDP/F group compared with baseline values, whereas 
no change was seen in the other two groups, suggesting that 
the extraﬁ  ne ﬁ  xed combination produced a lower inhibition 
of the hypothalamic-pituitary-adrenal axis compared with 
the other treatments. These results are in agreement with 
the low steroid intake that characterizes the BDP/F extraﬁ  ne 
formulation. Finally, no clinically signiﬁ  cant abnormalities 
of serum potassium and glucose were detected.
Two head-to-head clinical trials assessed the efﬁ  cacy and 
tolerability of BDP/F vs budesonide/formoterol (BUD/F) and 
ﬂ  uticasone propionate/salmeterol (FP/S), the currently mar-
keted ICS/LABA ﬁ  xed combinations (Papi et al 2007a, b). 
The two studies shared a similar study design. Subjects were 
allowed to enter the studies only if they had asthma symp-
toms and lung function (FEV1) 80% of predicted despite 
receiving up to 1000 μg/day BDP or equivalent. In the ﬁ  rst 
trial (Papi et al 2007a), patients given BDP/F as 2 inhalations 
twice daily showed improvement in lung function, measured 
by morning pre-dose PEF, which was comparable with that 
with an equipotent regimen of BUD/F 200/6 μg administered 
as 2 inhalations twice daily. Notably, when the speed of 
bronchodilation was evaluated as the change in FEV1 in the 
ﬁ  rst 60 min after the morning dose on the ﬁ  rst and last days of 
treatment, BDP/F demonstrated an onset of action equivalent 
to that of BUD/F. Both therapies were equally effective at 
improving asthma symptoms and increasing the percentage 
of days without the use of rescue medication (Table 2).
In the second trial (Papi et al 2007b), BDP/F was com-
pared with ﬂ  uticasone propionate/salmeterol (FP/S) pMDI 
125/25 μg, both administered as 2 puffs twice daily. BDP/F 
demonstrated improvement in PEF and FEV1 comparable to 
that of FP/S when lung function was measured pre-dosing. 
The onset of bronchodilation, evaluated as a change in FEV1 
in the ﬁ  rst 60 min after the morning dose on the ﬁ  rst and 
Table 2 Percentage of symptom-free days and days with no intake 
of rescue salbutamol during head-to-head clinical trial of BDP/F vs 
BUD/F in asthma (Derived from data of Papi et al 2007a)
Symptom-free 
days (%)
Days with no intake 
of rescue salbutamol (%)
BDP/F
 Baseline 2.61 1.62
 Last  2  weeks 41.93a 52.07a
BUD/F
 Baseline 3.52 2.97
 Last  2  weeks 37.75a 48.92a
ap  0.001 vs baseline, no signiﬁ  cant difference between treatments.Values are the 
mean values of the last week of the run-in period (baseline) and the last 2 weeks 
of treatment.
Abbreviations: BDP/F,   beclomethasone dipropionate/formoterol;   BUD/F, 
budesonide/formoterol.Therapeutics and Clinical Risk Management 2008:4(5) 861
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last days of treatment, was signiﬁ  cantly faster with BDP/F 
than with FP/S owing to the pharmacodynamic properties of 
formoterol. This treatment can promote adherence in view of 
the fact that up to 90% of patients want to take treatments that 
provide immediate relief (Partridge et al 2006). For asthma 
control, assessed as days without symptoms and days without 
rescue use of salbutamol, comparable improvements were 
shown in the BDP/F and FP/S groups (Table 3). Notably, 
a greater improvement in forced vital capacity was shown 
in the BDP/F group, possibly suggesting a greater effect 
on peripheral airways (van Aalderen et al 2007) (Figure 4).
In both studies no signiﬁ  cant differences in the rate 
and severity of asthma exacerbations or in the incidence 
of adverse events were detected. Finally, even if these two 
comparative trials were powered for non-inferiority testing, 
the number of subjects evaluated give the studies 85% 
power to show equivalence, with the original statistical 
assumptions (difference between treatments in morning 
PEF 20 L/min, with a standard deviation of 45 L/min at an 
alpha level of 0.05). Because the 95% conﬁ  dence intervals 
of the difference in the primary variable between treatments 
were within the pre-deﬁ  ned interval (±20 L/min), both stud-
ies would have supported an equivalence hypothesis (Papi 
et al 2007a, b).
Patient considerations
Drugs don’t work in patients who don’t take them.
C Everett Koop, MD
This sentence introduces an article published in the N Engl 
J Med (Osterberg and Blaschke 2005) that highlights the 
importance of a patient’s adherence to prescribed medications 
and its contribution to clinical success. Indeed, patients are a 
great part of the success or failure of therapy, and clinicians 
should always take this into account. It is often easier to 
respond to a patient’s complaint that the medication is not 
working by simply writing a prescription for a higher dose or 
a different medication. Lack of efﬁ  cacy with inhaled therapy 
can have several causes, not all related to pharmacological 
aspects of the drugs (Rubin 2004). For example, patients 
who cannot feel the medication working are more prone to 
non-adherence, particularly with ICS. This could explain 
why bronchodilators are sometimes overused by patients. 
The presence of the fast-acting bronchodilator formoterol in 
the BDP/F combination can therefore contribute to improved 
adherence because patients are more willing to take treat-
ments that provide immediate relief (Partridge et al 2006; 
Haahtela et al 2006).
Another aspect that may affect  adherence to therapy is 
the patient’s preference. A study to assess the acceptance 
of patients when changing from a CFC-driven device to a 
new HFA pMDI demonstrated that the HFA pMDI was the 
ﬁ  rst choice of patients by virtue of past experience (Hartung 
et al 2002). The characteristics of the BDP/F extrafine 
combination may be helpful to some patients. For example, 
the slower velocity and longer duration of the plume may 
facilitate hand–breath coordination, thereby improving the 
patient’s ability to use the device correctly.
Furthermore, unlike other pMDI suspensions, the BDP/F 
combination might not require down-titration of the thera-
peutic dose when used with a spacer. The more efﬁ  cient lung 
deposition when a spacer is used may cause an increase in 
systemic drug exposure. Interestingly, BDP/F extraﬁ  ne used 
with a spacer shows only slightly increased lung deposition, 
suggested by the peak in plasma drug concentration, with no 
signiﬁ  cant difference in 24 h systemic exposure to the active 
metabolite of BDP (B-17-MP) or formoterol (Figure 5) (Poli 
et al 2007). Finally, the solution formulation eliminates the 
need to shake the device before inhalation, which is manda-
tory for suspensions and is commonly overlooked by patients, 
resulting in variable dose delivery.
Some clinical improvements have been demonstrated for the 
BDP/F combination that could be due to the properties of the 
extraﬁ  ne solution formulation. First, whereas a higher adherence 
to therapy is expected for all ﬁ  xed combinations because of 
the convenience of a single inhaler instead of two, BDP/F 
is the ﬁ  rst combination to show signiﬁ  cant improvement in 
asthma control measures as compared to separate inhalers 
(Bonnet-Gonod et al 2006b; Fabbri et al 2008). Second, the 
reduced BDP dose – a consequence of the improved drug 
delivery of the formulation – allows the use of lower doses 
Table 3 Percentage of symptom-free days and days with no intake 
of rescue salbutamol during head-to-head clinical trial of BDP/F vs 
FP/S in asthma (Derived from data of Papi et al 2007b)
Symptom-free 
days (%)
Days with no intake 
of rescue salbutamol (%)
BDP/F
 Baseline 0.25 0
  Last 2 weeks 55.52a 60.65a
FP/S
 Baseline 0.84 1.15
  Last 2 weeks 54.25a 62.14a
ap  0.001 vs baseline, no signiﬁ  cant difference between treatments.Values are the 
mean values of the last week of the run-in period (baseline) and the last 2 weeks 
of treatment.
Abbreviations: BDP/F,   beclomethasone dipropionate/formoterol;   BUD/F, 
budesonide/formoterol.Therapeutics and Clinical Risk Management 2008:4(5) 862
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of ICS with resulting advantages in safety and adherence. 
Clinical effects of ICS are evident even at low doses, because 
the dose-response curve is steep for low doses and rapidly 
ﬂ  attens, whereas systemic side effects are dose dependent. 
The safety proﬁ  le of the BDP/F combination seems to be 
improved, as suggested by a lower systemic exposure to 
B-17-MP, which is potentially responsible for systemic side 
effects. Lower steroid exposure was demonstrated for 24 h 
serum cortisol in the pharmacokinetics study and for morn-
ing serum cortisol in the 6-month study. As long as one 
of the reasons for poor adherence to ICS treatment is that 
patients are concerned about side effects (Rubin 2004), the 
lower dose of BDP in this formulation could help to improve 
adherence.
Together with the slower plume velocity and the reduced 
particle size of the emitted drug, the lower nominal dose 
of BDP in the BDP/F combination leads to a reduction in 
the amount of drug deposited in the oropharynx because 
of inertial impact. This could be an advantage, because the 
drug deposited in the upper airways is responsible for local 
side effects such as hoarseness, dysphonia, and candidiasis 
(Roland et al 2004).
Histological and functional evidence suggests that the 
small airways are an important site of airway inﬂ  ammation in 
asthma. Reaching the more peripheral airways could therefore 
translate into higher efﬁ  cacy of the inhaled therapy (Pritchard 
and Sharma 2001). For patient-centered outcomes, clinically 
important improvements in quality of life (evaluated by the 
Asthma Quality of Life Questionnaire score) were observed 
after 1 year of treatment with extraﬁ  ne BDP compared with 
equipotent (double) doses of non-extraﬁ  ne CFC BDP. Con-
ventional clinical indexes of pulmonary function and asthma 
control were similar in the two groups (Juniper et al 2002). 
Recently, a subgroup analysis of an open label study indicated 
that patients receiving LABAs and treated with extraﬁ  ne 
BDP had signiﬁ  cantly greater improvement in asthma con-
trol, the ultimate measure of therapeutic efﬁ  cacy, compared 
with ﬂ  uticasone DPI. This suggests that there are potential 
advantages to extraﬁ  ne aerosols as part of the optimization 
of antiinﬂ  ammatory treatment (Molimard et al 2005).
Conclusion
When a new drug is marketed, clinicians may be concerned 
that it will have lower efﬁ  cacy or a higher risk of adverse 
events than already available drugs in the same therapeutic 
indication. Because BDP and formoterol are not new 
chemical entities, they are not likely to expose patients to 
the risk of unexpected or unknown side effects.
Figure 4 Forced vital capacity (FVC, L) measured at clinics in the two groups (BDP/F: 
y––y; FP/S: ◊----◊); *p  0.001 vs baseline; #p = 0.040 between treatments. Derived 
from data of Papi et al 2007b.
Abbreviation: BDP/F, beclomethasone dipropionate/formoterol; FP/S, ﬂ  uticasone 
propionate/salmeterol.
Figure 5 Area under the curve from time 0 to the last detectable drug concentration value (AUC0–t) for beclomethasone-17-monopropionate (B-17-MP) (left) and formoterol 
(right), after 4 inhalations of BDP/F 100/6 μg, with standard actuator (pMDI) or standard actuator with Aerochamber Plus (pMDI + spacer). From Poli et al 2007. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; pMDI, pressurized metered dose inhaler.
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Despite reassuring data on this topic (Allen et al 1994; 
Inoue et al 1999; Leone et al 2003; Pedersen 2006), a 
patient’s concern about a medication’s side effects, espe-
cially with corticosteroids, can be a cause of non-adherence 
and a resulting lack of efﬁ  cacy. Issues about the safety 
of ICS, especially for long-term treatments, have been 
debated for years. However, all asthma guidelines now 
recommend low doses of ICS as the mainstay of therapy, 
since it has been strongly proved that the beneﬁ  ts largely 
overcome the risks, even in children (Becker et al 2005; 
British Thoracic Society 2007; GINA 2007; NAEPP 2007). 
The clinical effects of the BDP/F combination are in line 
with current guidelines that recommend adding a LABA 
for those patients whose asthma is uncontrolled after an 
introductory dose of ICS, instead of increasing the dose 
of ICS. The efﬁ  cacy and safety of BDP/F are equivalent 
to those of already available combinations (Papi et al 
2007a, b). Therefore, the BDP/F ﬁ  xed combination seems 
to be a valuable option in the treatment of asthma, satisfy-
ing patients’ needs for improved efﬁ  cacy, improved safety 
proﬁ  le and ease of use.
Disclosures
Dr Nicolini and Dr Bizzi are employees of Chiesi Farmaceutici, 
the commercial entity that produces BDF/F combination.
Prof Papi has served as a consultant to Chiesi Farma-
ceutici and GlaxoSmithKline; has been paid lecture fees by 
AstraZeneca, Chiesi Farmaceutici, Boehringer Ingelheim, 
GlaxoSmithKline, and Merck Sharp and Dohme; and has 
received grant support from AstraZeneca, Chiesi Farmaceu-
tici, Boehringer Ingelheim, Merck Sharp and Dohme, and 
the Italian Ministry for University and Research.
Dr Scichilone has been paid lecture fees by Chiesi 
Farmaceutici, GlaxoSmithKline, Pﬁ  zer, and Sigma Tau, and 
has received grant support from Boehringer Ingelheim and 
Chiesi Farmaceutici.
Prof Fabbri has served as a consultant to Altana Pharma, 
AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, 
GlaxoSmithKline, Merck Sharp and Dohme, Novartis, 
Roche, and Pﬁ  zer; has been paid lecture fees by Altana 
Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi 
Farmaceutici, GlaxoSmithKline, Merck Sharp and Dohme, 
Novartis, Roche, and Pﬁ  zer; and has received grant support 
from Altana Pharma, AstraZeneca, Boehringer Ingelheim, 
Menarini, Miat, Schering Plough, Chiesi Farmaceutici, 
GlaxoSmithKline, Merck Sharp and Dohme, UCB Pharma, 
Pﬁ  zer, Italian Ministry of Health, and the Italian Ministry 
for University and Research.
References
Acerbi D, Brambilla G, Kottakis I. 2007. Advances in asthma and COPD 
management: delivering CFC-free inhaled therapy using Modulite 
technology. Pulm Pharmacol Ther, 20:290–303.
Allen DB, Mullen M, Mullen B. 1994. A meta-analysis of the effect of 
oral and inhaled corticosteroids on growth. J Allergy Clin Immunol, 
93:967–76.
Anderson PJ. 2001. Delivery options and devices for aerosolized therapeu-
tics. Chest, 120(3 Suppl):89S–93S.
Barnes PJ. 1995. Inhaled glucocorticoids for asthma. N Engl J Med, 
332:868–75.
Barnes PJ. 2002. Scientiﬁ  c rationale for inhaled combination therapy 
with long-acting beta2-agonists and corticosteroids. Eur Respir J, 
19:182–91.
Bateman ED, Boushey HA, Bousquet J, et al. 2004. Can guideline-deﬁ  ned 
asthma control be achieved? The Gaining Optimal Asthma ControL 
study. Am J Respir Crit Care Med, 170:836–44.
Becker A, Lemière C, Bérubé D, et al. 2005. Summary of recommenda-
tions from the Canadian Asthma Consensus guidelines, 2003. CMAJ, 
173(6 Suppl):S3–11.
Bonnet-Gonod F, Kottakis I, Ballabio M, et al. 2006a. Superior efﬁ  cacy 
of a low daily dose of a new ﬁ  xed combination of beclomethasone 
dipropionate/formoterol pMDI compared to increased daily dose of 
BDP in moderate persistent asthma: a 3 month clinical study (abstract). 
Eur Respir J, 28(Suppl 50):P1237.
Bonnet-Gonod F, Kottakis I, Hofman T, et al. 2006b. Beclomethasone 
dipropionate/formoterol in a single inhaler improves lung function and 
clinically meaningful outcomes in moderate to severe asthma (abstract). 
Eur Respir J, 28(Suppl 50):P1230.
Bousquet J, Cantini L. 2002. Clinical studies in asthmatics with a new 
non-extraﬁ  ne HFA formulation of beclometasone dipropionate (BDP 
Modulite). Respir Med, 96(Suppl D):S17–27.
British Thoracic Society. 2007. British guideline on the management of 
asthma. A national clinical guideline. Edinburgh (Scotland): Scottish 
Intercollegiate Guidelines Network (SIGN).
Brocklebank D, Ram F, Wright J, et al. 2001. Comparison of the effectiveness 
of inhaler devices in asthma and chronic obstructive airways disease: a 
systematic review of the literature. Health Technol Assess, 5:1–149.
Caramori G, Ito K, Papi A, et al. 2006. Interactions between long-acting 
β2-agonists and glucocorticoids. Drug Discov Today Ther Strateg, 
3:261–8.
Cazzoletti L, Marcon A, Janson C, et al. 2007. Asthma control in Europe: a 
real-world evaluation based on an international population-based study. 
J Allergy Clin Immunol 120:1360–7.
Descalzi D, Folli C, Nicolini G, et al. 2008. Anti-proliferative and anti-
remodelling effect of beclomethasone dipropionate, formoterol and 
salbutamol alone or in combination in primary human bronchial ﬁ  bro-
blasts. Allergy, 63:432–7.
Dhillon S, Keating GM 2006. Beclomethasone dipropionate/formoterol: 
in an HFA-propelled pressurised metered-dose inhaler. Drugs, 
66:1475–83.
Dolovich MB, Ahrens RC, Hess DR, et al. 2005. Device selection and 
outcomes of aerosol therapy: Evidence-based guidelines: American 
College of Chest Physicians/American College of Asthma, Allergy, 
and Immunology. Chest, 127:335–71.
Eickelberg O, Roth M, Lörx R, et al. 1999. Ligand-independent activation 
of the glucocorticoid receptor by beta2-adrenergic receptor agonists 
in primary human lung ﬁ  broblasts and vascular smooth muscle cells. 
J Biol Chem, 274:1005–10.
Fabbri LM, Nicolini G, Olivieri D, et al. 2008. Inhaled beclometasone 
dipropionate/formoterol extraﬁ  ne ﬁ  xed combination in the treatment of 
asthma: evidence and future perspectives. Expert Opin Pharmacother, 
9:479–90.
Gershman NH, Liu H, Wong HH, et al. 1999. Fractional analysis of 
sequential induced sputum samples during sputum induction: evidence 
that different lung compartments are sampled at different time points. 
J Allergy Clin Immunol, 104:322–8.Therapeutics and Clinical Risk Management 2008:4(5) 864
Nicolini et al
GINA (Global Initiative on Asthma), National Institutes of Health, National 
Heart Lung and Blood Institute, NHLBI/WHO Workshop Report. 
Global strategy for asthma management and prevention. NHLBI/WHO 
workshop report no. 02-3659, January 1995, updated 2007.
Giraud V, Roche N. 2002. Misuse of corticosteroid metered-dose inhaler is 
associated with decreased asthma stability. Eur Respir J, 19:246–51.
Haahtela T, Tamminen K, Malmberg LP, et al. 2006. Formoterol as needed 
with or without budesonide in patients with intermittent asthma 
and raised NO levels in exhaled air: a SOMA study. Eur Respir J, 
28:748–55.
Hamid Q, Song Y, Kotsimbos TC, et al. 1997. Inﬂ  ammation of small airways 
in asthma. J Allergy Clin Immunol, 100:44–51.
Hartung TK, Allbutt H, Dewar M, et al. 2002. Moving from CFC aerosol 
to HFA aerosol or dry powder inhalers: what do patients think? 
Respiration, 69:314–9.
Hauber H, Taha R, Bergeron C, et al. 2006. Effects of hydroﬂ  uoroalkane 
and dry powder-formulated corticosteroids on sputum inﬂ  ammatory 
markers in asthmatic patients. Can Respir J, 13:73–8.
Inoue T, Doi S, Takamatsu I, et al. 1999. Effect of long-term treatment with 
inhaled beclomethasone dipropionate on growth of asthmatic children. 
J Asthma, 36:159–64.
Janssens W, VandenBrande P, Hardeman E, et al. 2008. Inspiratory ﬂ  ow 
rates at different levels of resistance in elderly COPD patients. Eur 
Respir J. 31:78–83.
Juniper EF, Price DB, Stampone PA, et al. 2002. Clinically important 
improvements in asthma-speciﬁ  c quality of life, but no difference in 
conventional clinical indexes in patients changed from conventional 
beclomethasone dipropionate to approximately half the dose of extraﬁ  ne 
beclomethasone dipropionate. Chest, 121:1824–32.
Leone FT, Fish JE, Szeﬂ  er SJ, et al. 2003. Systematic review of the evidence 
regarding potential complications of inhaled corticosteroid use in asthma: 
collaboration of American College of Chest Physicians, American 
Academy of Allergy, Asthma, and Immunology, and American College 
of Allergy, Asthma, and Immunology. Chest, 124:2329–40.
Mariotti F, Poli G, Acerbi D, et al. 2007 Lung deposition of BDP/formoterol 
HFA pMDI in healthy volunteers, asthmatic and COPD patients 
[abstract]. Poster presented at the VIII UIP National congress, Florence, 
4–7 December 2007.
McGavin JK, Goa KL, Jarvis B. 2001. Inhaled budesonide/formoterol 
combination. Drugs, 61:71–8.
Molimard M, Martinat Y, Rogeaux Y, et al. 2005. Improvement of asthma 
control with beclomethasone extraﬁ  ne aerosol compared to ﬂ  uticasone 
and budesonide. Respir Med, 99:770–8.
NAEPP (National Asthma Education and Prevention Program). 2007. 
Expert Panel Report 3. Guidelines for the Diagnosis and Manage-
ment of Asthma – Summary Report 2007. J Allergy Clin Immunol, 
120(5 Suppl):S94–138.
Newman SP. 1990. Metered dose pressurized aerosols and the ozone layer. 
Eur Respir J. May; 3(5):495–7.
O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. 2001. Low dose inhaled 
budesonide and formoterol in mild persistent asthma: the OPTIMA 
randomized trial. Am J Respir Crit Care Med, 164:1392–7.
Osterberg L, Blaschke T. 2005. Adherence to medication. N Engl J Med, 
353:487–97.
Papi A, Paggiaro PL, Nicolini G, et al. 2007a. Beclomethasone/formoterol 
versus budesonide/formoterol combination therapy in asthma. Eur 
Respir J, 29:682–9.
Papi A, Paggiaro PL, Nicolini G, et al. 2007b. Beclomethasone/formoterol 
versus ﬂ  uticasone/salmeterol inhaled combination in moderate to severe 
asthma. Allergy, 62:1182–8.
Partridge MR, van der Molen T, Myrseth SE, et al. 2006. Attitudes and 
actions of asthma patients on regular maintenance therapy the INSPIRE 
study. BMC Pulm Med, 6:13.
Pedersen S. 2006. Clinical safety of inhaled corticosteroids for asthma in 
children: an update of long-term trials. Drug Saf, 29:599–612.
Poli G, Acerbi D, Nollevaux F. 2006. Pharmacokinetics and pharmacody-
namics of a new beclomethasone dipropionate and formoterol CFC-
free ﬁ  xed combination in healthy volunteers (abstract). Eur Respir J, 
28(Suppl 50):P3869.
Poli G, Acerbi D, Rusca A. 2007. Pharmacokinetics and lung bioavailability 
of Foster using the standard actuator or the Aerochamber Plus spacer 
(abstract). Eur Respir J, 30(Abstract Suppl):P2117.
Prenner BM. 2007. Formoterol dry-powder inhaler for the treatment of 
asthma and chronic obstructive pulmonary disease. Expert Opin 
Pharmacother, 8:3069–84.
Pritchard JN, Sharma RK. 2001. Introduction: inhaled drug delivery. 
J Aerosol Med, 14(Suppl 1):S1–2.
Proﬁ  ta M, Gagliardo R, Di Giorgi R, et al. 2005. Biochemical interaction 
between effects of beclomethasone dipropionate and salbutamol or 
formoterol in sputum cells from mild to moderate asthmatics. Allergy, 
60:323–9.
Rabe KF, Vermeire PA, Soriano JB, et al. 2000. Clinical management of 
asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) 
study. Eur Respir J, 16:802–7.
Rabe KF, Atienza T, Magyar P, et al. 2006. Effect of budesonide in combi-
nation with formoterol for reliever therapy in asthma exacerbations: a 
randomised controlled, double-blind study. Lancet, 368:744–53.
Rigamonti E, Kottakis I, Pelc M, et al. 2006. Comparison of a new extraﬁ  ne 
beclomethasone dipropionate HFA 134a-formulated pMDI with a 
standard BDP CFC pMDI in adults with moderate persistent asthma 
(abstract). Eur Respir J, 28(Suppl 50):P1236.
Roland NJ, Bhalla RK, Earis J. 2004. The local side effects of inhaled 
corticosteroids: current understanding and review of the literature. 
Chest, 126:213–9.
Rubin BK. 2004. What does it mean when a patient says, “my asthma 
medication is not working”? Chest, 126:972–81.
Scott MG, Swan C, Wheatley AP, et al. 1999. Identiﬁ  cation of novel 
polymorphisms within the promoter region of the human beta2 adren-
ergic receptor gene. Br J Pharmacol, 126:841–4.
Selroos O, Pietinalho A, Riska H. 1996. Delivery devices for inhaled asthma 
medication. Clinical implications of differences in effectiveness. Clin 
Immunother, 4:273–99.
Singh D, Piccinno A, Borrill Z, et al. 2008. Tolerability of high cumulative 
doses of the HFA modulite beclomethasone dipropionate/formoterol 
combination inhaler in asthmatic patients. Pulm Pharmacol Ther, 
21:551–7.
Suissa S, Ernst P, Benayoun S, et al. 2000. Low-dose inhaled corticosteroids 
and the prevention of death from asthma. N Engl J Med, 343:332–6.
Tarsin WY, Pearson SB, Assi KH, et al. 2006. Emitted dose estimates from 
Seretide Diskus and Symbicort Turbuhaler following inhalation by 
severe asthmatics. Int J Pharm, 316:131–7.
Tulic MK, Christodoulopoulos P, Hamid Q. 2001. Small airway inﬂ  amma-
tion in asthma. Respir Res, 2:333–9.
Van Aalderen WM, Price D, De Baets FM, et al. 2007. Beclometasone 
dipropionate extraﬁ  ne aerosol versus ﬂ  uticasone propionate in children 
with asthma. Respir Med, 101:1585–93.
Vanden Burgt JA, Busse WW, Martin RJ, et al. 2000. Efﬁ  cacy and safety 
overview of a new inhaled corticosteroid, QVAR (hydroﬂ  uoroalkane-
beclomethasone extraﬁ  ne inhalation aerosol), in asthma. J Allergy Clin 
Immunol, 106:1209–26.
Van der Palen J, Klein JJ, van Herwaarden CL, et al. 1999. Multiple inhalers 
confuse asthma patients. Eur Respir J, 14:1034–7.
Vastagh E, Kuna P, Calistruc P, et al. 2003. Efﬁ  cacy and safety of inhaled 
budesonide delivered once or twice daily via HFA-134a in mild to mod-
erate persistent asthma in adult patients. Comparison with budesonide 
CFC. Respir Med, 97(Suppl D):S20–8.
Virchow JC, Crompton GK, Dal Negro R, et al. 2008. Importance of inhaler 
devices in the management of airway disease. Respir Med, 102:10–9.
Wieshammer S, Dreyhaupt J. 2008. Dry powder inhalers: which factors 
determine the frequency of handling errors? Respiration, 75:18–25.